|
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
|
|
|
Item 2.02 |
Results of Operations and Financial Condition.
|
Item 9.01 |
Financial Statements and Exhibits.
|
Exhibit Number
|
Description
|
|
Press Release dated November 15, 2021
|
Galectin Therapeutics Inc.
|
|||
Date: November 15, 2021
|
By:
|
/s/ Jack W. Callicutt
|
|
Jack W. Callicutt
|
|||
Chief Financial Officer
|
Three Months Ended
September 30,
|
Nine Months Ended
September 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
(in thousands, except per share data)
|
||||||||||||||||
Operating expenses:
|
||||||||||||||||
Research and development
|
$
|
6,613
|
$
|
4,780
|
$
|
17,962
|
$
|
11,605
|
||||||||
General and administrative
|
1,631
|
1,146
|
4,792
|
4,007
|
||||||||||||
Total operating expenses
|
8,244
|
5,926
|
22,754
|
15,612
|
||||||||||||
Total operating loss
|
(8,244
|
)
|
(5,926
|
)
|
(22,754
|
)
|
(15,612
|
)
|
||||||||
Other income (expense):
|
||||||||||||||||
Interest income
|
1
|
5
|
3
|
64
|
||||||||||||
Interest expense
|
(111
|
)
|
(22
|
)
|
(217
|
)
|
(65
|
)
|
||||||||
Change in fair value of derivative
|
(166
|
)
|
-
|
-
(338)
|
|
-
|
||||||||||
Total other income
|
(276
|
)
|
(17
|
)
|
(552
|
)
|
(1
|
)
|
||||||||
Net loss
|
$
|
(8,520
|
)
|
$
|
(5,943
|
)
|
$
|
(23,306
|
)
|
$
|
(15,613
|
)
|
||||
Preferred stock dividends
|
(37
|
)
|
(12
|
)
|
(104
|
)
|
(72
|
)
|
||||||||
Warrant modification
|
||||||||||||||||
Net loss applicable to common stock
|
$
|
(8,557
|
)
|
$
|
(5,955
|
)
|
$
|
(23,410
|
)
|
$
|
(15,685
|
)
|
||||
Basic and diluted net loss per share
|
$
|
(0.14
|
)
|
$
|
(0.10
|
)
|
$
|
(0.40
|
)
|
$
|
(0.28
|
)
|
||||
Shares used in computing basic and diluted net loss per share
|
59,290
|
57,047
|
58,253
|
57,013
|
September 30, 2021
|
December 31, 2020
|
|||||||
(in thousands)
|
||||||||
Cash and cash equivalents
|
$
|
36,600
|
$
|
27,142
|
||||
Total assets
|
38,038
|
29,600
|
||||||
Total current liabilities
|
8,299
|
5,399
|
||||||
Total liabilities
|
28,789
|
5,407
|
||||||
Total redeemable, convertible preferred stock
|
1,723
|
1,723
|
||||||
Total stockholders’ equity
|
$
|
7,526
|
$
|
22,470
|